Equally, single-drug/high-dose MMC protocols showed a borderline significant improved OS compared to either single-drug/low-dose or double-drug MMC-HIPEC protocols (median OS 45 months (95% c.i. 40 to 52 months) versus 36 months (95% c.i. 30 to 42 months) versus 35 months (95% c.i. 22 to 94 months), P = 0.05, respectively, Fig. 4c ).
1
—
—